相关实验视频

Updated: Jan 9, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.2K

新型多巴胺4受体连接体在自发高血压大鼠中差异改善了类似ADHD的行为

Ike C de la Peña, Samantha Andino, Ashley Amis

    bioRxiv : the preprint server for biology
    |December 8, 2025
    PubMed
    概括

    新型多巴胺D4受体 (D4R) 药物显示为治疗注意力缺陷/多动障碍 (ADHD) 的非兴奋剂治疗有前途. 部分激动剂和对抗剂都改善了大鼠的ADHD类行为,对对照组的影响最小,这表明病理特异性疗效.

    更多相关视频

    Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology07:25

    Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

    Published on: March 27, 2018

    8.9K
    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    3.3K

    相关概念视频

    Attention-Deficit/Hyperactivity Disorder01:30

    Attention-Deficit/Hyperactivity Disorder

    Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
    Diagnostic Criteria and Symptoms
    To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
    718
    Adrenergic Agonists: Indirect-Acting Agents01:25

    Adrenergic Agonists: Indirect-Acting Agents

    Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
    One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
    2.5K
    Drugs Affecting Neurotransmitter Synthesis01:29

    Drugs Affecting Neurotransmitter Synthesis

    Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
    2.1K
    Drugs Affecting Neurotransmitter Release or Uptake01:21

    Drugs Affecting Neurotransmitter Release or Uptake

    Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
    1.5K
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
    945
    Adrenergic Agonists: Direct-Acting Agents01:30

    Adrenergic Agonists: Direct-Acting Agents

    Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
    These agents can be classified...
    2.6K